A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma

Inclusion Criteria: * Histologically confirmed Hodgkin's lymphoma or Non-Hodgkin's lymphoma receiving Q14, Q21, or Q28 day CHOP, ICE, ESHAP, or DHAP chemotherapy; with or without Rituximab * Has adequate bone marrow function; platelet count \> 100 x 10\^9/L on the day of initiation of the on study chemotherapy of the next treatment cycle and absolute neutrophil count, ANC \> or = 1 x 10\^9/L, and hemoglobin \> or = 9.5 g/dL * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Has adequate liver function * must be able to receive the same chemotherapy regimen during the first treatment cycle as was received during the prior qualifying cycle * must experience Common Terminology Criteria (CTC) grade 3 or 4 thrombocytopenia (platelet count \< 50 x 10\^9/L) as a result of the chemotherapy administered in the cycle immediately preceding study entry * has serum creatinine concentration \< or = 2 mg/dl Exclusion Criteria: * More that 1 prior relapse chemotherapy regimen * Sepsis, disseminated coagulation or any other condition that may exacerbate thrombocytopenia * Significant bleeding (CTC grade 3 or 4) * History of thromboembolic disease * Subjects who are identified by clinical history and/or serological testing to have either acute or chronic hepatitis B or C infection or to be HIV positive * Use of any nitrosourea or mitomycin-C * Has received any thrombocytopenic growth factor * Has received a marrow or peripheral blood stem cell infusion * Known hypersensitivity to any recombinant E. coli-derived product